Skip Navigation



JAC Advance Access published online on August 13, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn318
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/5/866    most recent
dkn318v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Phillips, D. R.
Right arrow Articles by Hay, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Phillips, D. R.
Right arrow Articles by Hay, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Leading article

Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy

David Richard Phillips1 and Phillip Hay1,2,*

1 Courtyard Clinic, St George's Hospital NHS Trust, Blackshaw Road, Tooting, London SW17 0QT, UK 2 Centre for Infection, St George's, University of London, London, UK

* Corresponding author. Tel: +44-208-725-1656; Fax: +44-208-725-2736; E-mail: phay{at}sgul.ac.uk

Lipoatrophy (LA) is a common and now well-recognized complication of highly active antiretroviral therapy (HAART). Over the last decade as knowledge of the mechanisms behind LA has developed, several antiretroviral drugs, in particular, have emerged as the likely agents responsible for this complication. This has been supported by studies comparing alternative HAART regimens and by those in which HAART regimens have been modified with a resulting impact on LA. In this article, we review the evidence underlying the current perspectives on the development of LA and the strategies employed to manage or avoid it.

Key Words: lipoatrophy , lipodystrophy , HAART , HIV , antiretrovirals


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.